Stocks On the Move: Depomed Inc, Interpace Diagnostics Group Inc, and Medtronic PLC

DEPO, IDXG, and MDT are among the stocks on the move today

Jan 3, 2017 at 2:14 PM
facebook twitter linkedin


U.S. stocks are modestly higher, fresh off a solid round of economic data. Among specific equities in focus today are drug stock Depomed Inc (NASDAQ:DEPO), molecular specialist Interpace Diagnostics Group Inc (NASDAQ:IDXG), and healthcare firm Medtronic PLC (NYSE:MDT). Here's a quick look at what's moving DEPO, IDXG, and MDT.

  • DEPO has jumped 10.7% to trade at $19.94, essentially closing a bearish gap from mid-December. Buoying the stock is a New York Post report, claiming KKR & Co. L.P. (NYSE:KKR) is interested in buying the drugmaker. Suffice it to say, Depomed Inc short sellers could be hitting the panic button. One-quarter of the stock's total float is sold short, which would take nearly eight sessions to cover, at DEPO's average daily trading rate.
  • IDXG has roughly tripled in value today at $13.15 -- after being repeatedly halted on volatility earlier -- with the company reaching an agreement with the Blue Cross Blue Shield Association's Center for Clinical Effectiveness to "support further coverage determinations." As such, the stock is on pace for its second highest settlement price in more than a year. This is bad news for a recent crop of Interpace Diagnostics Group Inc short sellers, however. While short interest is low on an absolute basis, these bearish bets soared a brow-raising 3,725% over the last two reporting periods.
  • MDT is down 0.8% at $70.69 -- after earlier touching an annual low of $69.35 -- on the heels of bearish brokerage attention. Specifically, J.P. Morgan Securities and Morgan Stanley lowered their ratings to the equivalent of a "hold" from a "buy," and slashed their price targets to $79 and $77, respectively. Explaining its bearish note, the former cited the "combination of a more challenging macro environment, likely downward revisions to FY18 consensus and the uncertainty of corporate tax reform." Given Medtronic PLC's technical weakness, the stock could soon succumb to additional downbeat brokerage notes. After all, 16 of 22 analysts rate MDT shares a "buy" or better.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Best stocks for October and worst stocks for October
 


 


 
Special Offers from Schaeffer's Trading Partners